Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape
Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK resistance patterns and the potential role of novel BTK degraders when selecting therapy for relapsed/refractory patients.
EP: 1.Fixed-Duration Options for CLL
EP: 2.Pirtobrutinib in the BRUIN CLL-321 Study
Now Viewing
EP: 3.Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape
EP: 4.Sequencing Considerations in Relapsed/Refractory CLL
EP: 5.Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL
EP: 6.Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL
EP: 7.The Inflation Reduction Act and Cost Considerations for BTK Inhibitors
EP: 8.Switching Between BTK Inhibitors in CLL
EP: 9.Discontinuing Versus Switching BTK Inhibitors for Toxicity
EP: 10.Opportunities for Easing BTK Inhibitor Switches
EP: 11.Reflections on 2024’s Progress in R/R CLL
Video content above is prompted by the following:
- With the recent NCCN update recommending pirtobrutinib as a second line or later option, and in light of the BRUIN CLL-321 data presented at the 2024 American Society of Hematology annual meeting, what factors should oncologists consider when incorporating newer agents like pirtobrutinib into the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)?
- What is the significance of novel Bruton tyrosine kinase (BTK) degraders such as NX-5948, and how might they fill therapeutic gaps in BTK-resistant or intolerant relapsed/refractory CLL populations?
Related Content
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Article
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
